Paola Brescia

Paola Brescia

Auto-generated profile, based on publicly available information

Paola Brescia

Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Journal of Hepatology
Verified
Journal Article
Open access
JMJuliette Mouries
Juliette Mouries
PBPaola Brescia
Paola Brescia
ASAlessandra Silvestri
Alessandra Silvestri
ISIlaria Spadoni
Ilaria Spadoni
MSMarcel Sorribas
Marcel Sorribas
MRMaria Rescigno
Maria Rescigno
Fatty liver disease, including non-alcoholic fatty liver (NAFLD) and steatohepatitis (NASH), has been associated with increased intestinal barrier permeability and translocation of bacteria or bacterial products into the blood circulation. In this study, we aimed to unravel the role of both intestinal barrier integrity and microbiota in NAFLD/NASH development. C57BL/6J mice were fed with high-fat diet (HFD) or methionine-choline-deficient diet for 1 week or longer to recapitulate aspects of NASH (steatosis, inflammation, insulin resistance). Genetic and pharmacological strategies were then used to modulate intestinal barrier integrity. We show that disruption of the intestinal epithelial barrier and gut vascular barrier (GVB) are early events in NASH pathogenesis. Mice fed HFD for only 1 week undergo a diet-induced dysbiosis that drives GVB damage and bacterial translocation into the liver. Fecal microbiota transplantation from HFD-fed mice into specific pathogen-free recipients induces GVB damage and epididymal adipose tissue enlargement. GVB disruption depends on interference with the WNT/β-catenin signaling pathway, as shown by genetic intervention driving β-catenin activation only in endothelial cells, preventing GVB disruption and NASH development. The bile acid analogue and farnesoid X receptor agonist obeticholic acid (OCA) drives β-catenin activation in endothelial cells. Accordingly, pharmacologic intervention with OCA protects against GVB disruption, both as a preventive and therapeutic agent. Importantly, we found upregulation of the GVB leakage marker in the colon of patients with NASH. We have identified a new player in NASH development, the GVB, whose damage leads to bacteria or bacterial product translocation into the blood circulation. Treatment aimed at restoring β-catenin activation in endothelial cells, such as administration of OCA, protects against GVB damage and NASH development. The incidence of fatty liver disease is reaching epidemic levels in the USA, with more than 30% of adults having NAFLD (non-alcoholic fatty liver disease), which can progress to more severe non-alcoholic steatohepatitis (NASH). Herein, we show that disruption of the intestinal epithelial barrier and gut vascular barrier are early events in the development of NASH. We show that the drug obeticholic acid protects against barrier disruption and thereby prevents the development of NASH, providing further evidence for its use in the prevention or treatment of NASH.

1 May 2021 in Cancer Cell
Verified
Journal Article
Closed access
ABAlice Bertocchi
Alice Bertocchi
SCSara Carloni
Sara Carloni
PRPaola Simona Ravenda
Paola Simona Ravenda
GBGiovanni Bertalot
Giovanni Bertalot
ISIlaria Spadoni
Ilaria Spadoni
MRMaria Rescigno
Maria Rescigno

24 April 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
PBPaola Brescia
Paola Brescia
BOBarbara Ortensi
Barbara Ortensi
LFLorenzo Fornasari
Lorenzo Fornasari
DLDaniel Levi
Daniel Levi
GBGiovanni Broggi
Giovanni Broggi
GPGiuliana Pelicci
Giuliana Pelicci
The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has been widely investigated, since it identifies cells that are able to initiate neurosphere growth and form heterogeneous tumors when transplanted in immune-compromised mice. However, evidences of CD133-negative cells exhibiting similar properties have also been reported. Moreover, the functional role of CD133 in cancer stem/progenitor cells remains poorly understood. We studied the biological effects of CD133 downregulation in GBM patient-derived neurospheres. Our results indicate that there is not a hierarchical relation between CD133-positive and CD133-negative cells composing the neurospheres. Indeed, CD133 appears in an interconvertible state, changing its subcellular localization between the cytoplasm and the plasmamembrane of neurosphere cells. Silencing of CD133 in human GBM neurospheres using lentivirus-mediated short hairpin RNA impairs the self-renewal and tumorigenic capacity of neurosphere cells. These results imply that CD133 could be used as a therapeutic target in GBMs.

1 September 2018 in Cancer Cell
Verified
Journal Article
Closed access
PBPaola Brescia
Paola Brescia
CSChristof Schneider
Christof Schneider
AHAntony B. Holmes
Antony B. Holmes
QSQiong Shen
Qiong Shen
SHShafinaz Hussein
Shafinaz Hussein
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera

10 October 2013 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MSMatteo Setti
Matteo Setti
NSNicoletta Savalli
Nicoletta Savalli
DODaniela Osti
Daniela Osti
CRCristina Richichi
Cristina Richichi
MAMarina Angelini
Marina Angelini
GPGiuliana Pelicci
Giuliana Pelicci
Chloride channels are physiologically involved in cell division and motility. Chloride intracellular channel 1 (CLIC1) is overexpressed in a variety of human solid tumors compared with normal tissues, suggesting a potential involvement of CLIC1 in the regulation of tumorigenesis. This led us to investigate the role of CLIC1 in gliomagenesis. We used the neurosphere system to isolate stem/progenitor cells from human glioblastomas (GBMs). CLIC1 targeting in GBM neurospheres was achieved by both lentiviral-mediated short-hairpin RNA transduction and CLIC1 antibody treatment, and its effect on stem-like properties was analyzed in vitro by proliferation and clonogenic assays and in vivo by orthotopic injection in immunocompromised mice. Channel activity was studied by perforated patch clamp technique. Differences in expression were analyzed by analysis of variance with Tamhane’s multiple comparison test. Kaplan–Meier analyses and log-rank test were used to assess survival. All statistical tests were two-sided. CLIC1 was statistically significantly overexpressed in GBMs compared with normal brain tissues ( P < .001) with a better survival of patients with CLIC1 low-expressing tumors (CLIC1 low vs CLIC1 high survival: χ 2 = 74.35; degrees of freedom = 1; log-rank P < .001). CLIC1 was variably expressed in patient-derived GBM neurospheres and was found enriched in the stem/progenitor compartment. CLIC1 silencing reduced proliferative ( P < .01), clonogenic ( P < .01), and tumorigenic capacity ( P < .05) of stem/progenitor cells. The reduction of CLIC1 chloride currents with a specific CLIC1 antibody mirrored the biological effects of CLIC1 silencing in GBM patient–derived neurospheres. Reduced gliomagenesis after CLIC1 targeting in tumoral stem/progenitor cells and the finding that CLIC1 expression is inversely associated with patient survival suggest CLIC1 as a potential target and prognostic biomarker.

23 May 2012 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
PBPaola Brescia
Paola Brescia
CRCristina Richichi
Cristina Richichi
GPGiuliana Pelicci
Giuliana Pelicci
Cancer stem cells (CSCs) were isolated in multiple tumor types, including human glioblastomas, and although the presence of surface markers selectively expressed on CSCs can be used to isolate them, no marker/pattern of markers are sufficiently robust to definitively identify stem cells in tumors. Several markers were evaluated for their prognostic value with promising early results, however none of them was proven to be clinically useful in large-scale studies, leading to outstanding efforts to identify new markers. Given the heterogeneity of human glioblastomas further investigations are necessary to identify both cancer stem cell-specific markers and the molecular mechanisms sustaining the tumorigenic potential of these cells to develop tailored treatments. Markers for glioblastoma stem cells such as CD133, CD15, integrin-α6, L1CAM might be informative to identify these cells but cannot be conclusively linked to a stem cell phenotype. Overlap of expression, functional state and morphology of different subpopulations lead to carefully consider the techniques employed so far to isolate these cells. Due to a dearth of methods and markers reliably identifying the candidate cancer stem cells, the isolation/enrichment of cancer stem cells to be therapeutically targeted remains a major challenge.